Reported Earnings • Jul 27
First half 2026 earnings released: EPS: UK£0.14 (vs UK£0.55 in 1H 2025) First half 2026 results: EPS: UK£0.14 (down from UK£0.55 in 1H 2025). Revenue: UK£47.2m (down 17% from 1H 2025). Net income: UK£5.98m (down 76% from 1H 2025). Profit margin: 13% (down from 43% in 1H 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. New Risk • May 26
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 32% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 32% per year for the foreseeable future. High level of non-cash earnings (21% accrual ratio). Upcoming Dividend • May 14
Upcoming dividend of UK£0.10 per share Eligible shareholders must have bought the stock before 21 May 2026. Payment date: 02 July 2026. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.6%). Reported Earnings • Apr 24
Full year 2025 earnings released: EPS: UK£0.75 (vs UK£0.27 in FY 2024) Full year 2025 results: EPS: UK£0.75 (up from UK£0.27 in FY 2024). Revenue: UK£111.7m (flat on FY 2024). Net income: UK£33.3m (up 177% from FY 2024). Profit margin: 30% (up from 11% in FY 2024). Revenue is forecast to stay flat during the next 2 years compared to a 6.3% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to UK£6.12, the stock trades at a trailing P/E ratio of 7.6x. Average forward P/E is 14x in the Professional Services industry in the United Kingdom. Total returns to shareholders of 65% over the past three years. Declared Dividend • Mar 19
Dividend increased to UK£0.10 Dividend of UK£0.10 is 25% higher than last year. Ex-date: 21st May 2026 Payment date: 2nd July 2026 Dividend yield will be 1.9%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (19% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 36% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. New Risk • Mar 18
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 18
Full year 2025 earnings released: EPS: UK£0.75 (vs UK£0.27 in FY 2024) Full year 2025 results: EPS: UK£0.75 (up from UK£0.27 in FY 2024). Revenue: UK£111.7m (flat on FY 2024). Net income: UK£33.3m (up 177% from FY 2024). Profit margin: 30% (up from 11% in FY 2024). Revenue is forecast to stay flat during the next 2 years compared to a 6.5% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Price Target Changed • Mar 17
Price target increased by 14% to UK£8.00 Up from UK£6.99, the current price target is provided by 1 analyst. New target price is 48% above last closing price of UK£5.40. Stock is up 31% over the past year. The company posted earnings per share of UK£0.26 last year. Anuncio • Mar 11
Science Group plc to Report Fiscal Year 2025 Results on Mar 17, 2026 Science Group plc announced that they will report fiscal year 2025 results at 8:00 AM, GMT Standard Time on Mar 17, 2026 New Risk • Feb 13
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Buy Or Sell Opportunity • Aug 21
Now 20% undervalued Over the last 90 days, the stock has risen 20% to UK£5.60. The fair value is estimated to be UK£7.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to decline by 0.6% in a year. Earnings are forecast to decline by 62% in the next year. Reported Earnings • Jul 29
First half 2025 earnings released: EPS: UK£0.55 (vs UK£0.13 in 1H 2024) First half 2025 results: EPS: UK£0.55 (up from UK£0.13 in 1H 2024). Revenue: UK£57.2m (up 6.5% from 1H 2024). Net income: UK£24.7m (up 318% from 1H 2024). Profit margin: 43% (up from 11% in 1H 2024). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. New Risk • Jul 29
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 60% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 60% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Anuncio • Jun 11
WSP Group plc entered into an agreement to acquire 20% stake in Ricardo plc (LSE:RCDO) from Science Group plc (AIM:SAG) for £53.5 million. WSP Group plc entered into an agreement to acquire 20% stake in Ricardo plc (LSE:RCDO) from Science Group plc (AIM:SAG) for £53.5 million on June 11, 2025. A cash consideration valued at £4.3 per share will be paid by WSP Group plc. In a related transaction, WSP Group plc has agreed to acquire remaining stake in Ricardo plc at £4.3 per share. As of June 12, 2025, Science Group has notified Ricardo that its requisition notice has been withdrawn.
The transaction is subject to regulatory approvals and is expected to be completed in the fourth quarter of 2025.
RBC Capital Markets, London acted as financial advisor to WSP Group plc. Linklaters LLP acted as legal advisor to WSP Group plc. Gleacher Shacklock LLP, Investment Banking Arm led by James Dawson acted as financial advisor to Ricardo plc. Ashurst LLP acted as legal advisor to Ricardo plc. Upcoming Dividend • May 15
Upcoming dividend of UK£0.08 per share Eligible shareholders must have bought the stock before 22 May 2025. Payment date: 04 July 2025. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of British dividend payers (5.8%). In line with average of industry peers (1.9%). Anuncio • Apr 16
Science Group plc, Annual General Meeting, May 21, 2025 Science Group plc, Annual General Meeting, May 21, 2025. Location: 17 waterloo place, sw1y 4ar, london United Kingdom Anuncio • Mar 25
Science Group plc announces Annual dividend, payable on July 04, 2025 Science Group plc announced Annual dividend of GBP 0.0800 per share payable on July 04, 2025, ex-date on May 22, 2025 and record date on May 23, 2025. Reported Earnings • Mar 24
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: UK£0.27 (up from UK£0.12 in FY 2023). Revenue: UK£110.7m (down 2.4% from FY 2023). Net income: UK£12.0m (up 118% from FY 2023). Profit margin: 11% (up from 4.9% in FY 2023). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is forecast to grow 1.7% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Anuncio • Mar 20
Science Group plc to Report Fiscal Year 2024 Results on Mar 24, 2025 Science Group plc announced that they will report fiscal year 2024 results on Mar 24, 2025 Price Target Changed • Jan 13
Price target increased by 11% to UK£6.76 Up from UK£6.08, the current price target is an average from 3 analysts. New target price is 45% above last closing price of UK£4.65. Stock is up 19% over the past year. The company is forecast to post earnings per share of UK£0.23 for next year compared to UK£0.12 last year. Anuncio • Jul 26
Science Group plc (AIM:SAG) commences an Equity Buyback Plan for 4,570,200 shares, representing 10% of its issued share capital, under the authorization approved on June 18, 2024. Science Group plc (AIM:SAG) commences share repurchases on July 24, 2024, under the program mandated by the shareholders in the Annual General Meeting held on June 18, 2024. As per the mandate, the company is authorized to repurchase up to 4,570,200 shares, representing 10% of its issued share capital. The minimum price (exclusive of expenses) which may be paid for each ordinary share is £0.01 and the maximum price which may be paid for each ordinary share is the higher an amount equal to 105% of the average of the middle market quotations for an ordinary share as derived from the AIM Appendix of the Daily Official List of London Stock Exchange for the five business days immediately preceding the day on which the ordinary share is purchased and an amount equal to the higher of the price of the last independent trade of an ordinary share and the current highest independent bid for an ordinary share on the trading venue where the purchase is carried out. The shares purchased may either be cancelled or held as treasury shares, sold for cash or used to meet the company’s obligations under its employee share schemes. The authority shall expire at the conclusion of the next Annual General Meeting of the company or, if earlier, on June 30, 2025. As of May 17, 2024, the company had 46,185,874 ordinary shares in issue of which 483,875 ordinary shares are held in treasury. Reported Earnings • Jul 24
First half 2024 earnings released: EPS: UK£0.13 (vs UK£0.12 in 1H 2023) First half 2024 results: EPS: UK£0.13 (up from UK£0.12 in 1H 2023). Revenue: UK£53.7m (down 4.3% from 1H 2023). Net income: UK£5.90m (up 9.5% from 1H 2023). Profit margin: 11% (up from 9.6% in 1H 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 13
Upcoming dividend of UK£0.08 per share Eligible shareholders must have bought the stock before 20 June 2024. Payment date: 19 July 2024. Payout ratio is a comfortable 66% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of British dividend payers (5.6%). In line with average of industry peers (1.8%). Recent Insider Transactions • May 26
Group MD & Director recently sold UK£333k worth of stock On the 21st of May, Daniel Edwards sold around 72k shares on-market at roughly UK£4.64 per share. This transaction amounted to 48% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Daniel's only on-market trade for the last 12 months. Anuncio • May 23
Science Group plc, Annual General Meeting, Jun 18, 2024 Science Group plc, Annual General Meeting, Jun 18, 2024. Location: 17 waterloo place, sw1y 4ar, london United Kingdom Price Target Changed • Apr 24
Price target increased by 9.1% to UK£6.35 Up from UK£5.82, the current price target is an average from 2 analysts. New target price is 53% above last closing price of UK£4.15. Stock is up 3.5% over the past year. The company is forecast to post earnings per share of UK£0.23 for next year compared to UK£0.12 last year. Anuncio • Mar 23
Science Group plc Proposes Final Dividend for 2023, Payable on 19 July 2024 Science Group plc proposed final dividend for 2023 of 8.0 pence per share (2022: 5.0 pence per share). The dividend is subject to approval by shareholders at the next Annual General Meeting and the expected cost of £3.6 million has not been included as a liability as at 31 December 2023. The dividend will be payable on 19 July 2024 to shareholders on the register at the close of business on 21 June 2024. Reported Earnings • Mar 21
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: UK£0.12 (down from UK£0.23 in FY 2022). Revenue: UK£113.3m (up 31% from FY 2022). Net income: UK£5.52m (down 48% from FY 2022). Profit margin: 4.9% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 42%. Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Anuncio • Mar 19
Science Group plc to Report Fiscal Year 2023 Results on Mar 21, 2024 Science Group plc announced that they will report fiscal year 2023 results on Mar 21, 2024 New Risk • Feb 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.3% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). New Risk • Jan 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Recent Insider Transactions Derivative • Jul 30
Group MD & Director exercised options and sold UK£1.2m worth of stock On the 27th of July, Daniel Edwards exercised 333.33k options at around UK£0.01, then sold 292k of the shares acquired at an average of UK£4.00 per share and kept the remainder. For the year to December 2019, Daniel's total compensation was 57% salary and 43% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Daniel has owned 109.00k shares directly. Company insiders have collectively sold UK£1.2m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Jul 24
First half 2023 earnings released: EPS: UK£0.12 (vs UK£0.10 in 1H 2022) First half 2023 results: EPS: UK£0.12 (up from UK£0.10 in 1H 2022). Revenue: UK£56.1m (up 25% from 1H 2022). Net income: UK£5.39m (up 16% from 1H 2022). Profit margin: 9.6% (in line with 1H 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Anuncio • Jun 13
Science Group plc (AIM:SAG) commences an Equity Buyback for 4,537,134 shares, representing 10.01% of its issued share capital, , under the authorization approved on May 18, 2023. Science Group plc (AIM:SAG) commences share repurchases on June 9, 2023, under the program mandated by the shareholders in the Annual General Meeting held on May 18, 2023. As per the mandate, the company is authorized to repurchase up to 4,537,134 shares, representing 10% of its issued share capital. The minimum price (exclusive of expenses) which may be paid for each ordinary share is £0.01 and the maximum price which may be paid for each ordinary share is the higher an amount equal to 105% of the average of the middle market quotations for an ordinary share as derived from the AIM Appendix of the Daily Official List of London Stock Exchange for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased and an amount equal to the higher of the price of the last independent trade of an ordinary share and the current highest independent bid for an ordinary share as derived from the London Stock Exchange Trading System. The shares purchased may either be cancelled or held as treasury shares, which may then be cancelled, sold for cash or used to meet the company’s obligations under its employee share schemes. The authority shall expire at the conclusion of the next Annual General Meeting of the company or, if earlier, on June 30, 2024. As of April 14, 2023, the company had 46,185,874 ordinary shares in issue of which 841,533 ordinary shares are held in treasury. Board Change • May 26
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Susan Clement-Davies was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 11
Upcoming dividend of UK£0.05 per share at 1.2% yield Eligible shareholders must have bought the stock before 18 May 2023. Payment date: 16 June 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.4%). Reported Earnings • Mar 21
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: EPS: UK£0.23 (up from UK£0.22 in FY 2021). Revenue: UK£86.3m (up 6.3% from FY 2021). Net income: UK£10.6m (up 10% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 7.0%. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Professional Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Price Target Changed • Nov 16
Price target increased to UK£5.82 Up from UK£5.31, the current price target is provided by 1 analyst. New target price is 49% above last closing price of UK£3.90. Stock is down 14% over the past year. The company is forecast to post earnings per share of UK£0.23 for next year compared to UK£0.22 last year. Price Target Changed • Oct 31
Price target increased to UK£5.82 Up from UK£5.31, the current price target is an average from 2 analysts. New target price is 51% above last closing price of UK£3.85. Stock is down 16% over the past year. The company is forecast to post earnings per share of UK£0.23 for next year compared to UK£0.22 last year. Reported Earnings • Jul 26
First half 2022 earnings released: EPS: UK£0.10 (vs UK£0.11 in 1H 2021) First half 2022 results: EPS: UK£0.10 (down from UK£0.11 in 1H 2021). Revenue: UK£44.8m (up 10% from 1H 2021). Net income: UK£4.64m (flat on 1H 2021). Profit margin: 10% (down from 12% in 1H 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 1.4% compared to a 11% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Anuncio • Jul 24
Science Group plc to Report First Half, 2022 Results on Jul 25, 2022 Science Group plc announced that they will report first half, 2022 results on Jul 25, 2022 Anuncio • May 19
Science Group plc (AIM:SAG) commences an Equity Buyback Plan for 4,551,046 shares, representing 10% of its issued share capital, under the authorization approved on May 18, 2022. Science Group plc (AIM:SAG) commences share repurchases on May 18, 2022, under the program mandated by the shareholders in the Annual General Meeting held on May 18, 2022. As per the mandate, the company is authorized to repurchase up to 4,551,046 shares, representing 10% of its issued share capital. The minimum price (exclusive of expenses) which may be paid for each ordinary share is £0.01 and the maximum price which may be paid for each ordinary share is the higher an amount equal to 105% of the average of the middle market quotations for an ordinary share as derived from the AIM Appendix of the Daily Official List of London Stock Exchange for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased and an amount equal to the higher of the price of the last independent trade of an ordinary share and the current highest independent bid for an ordinary share as derived from the London Stock Exchange Trading System. The shares purchased may either be cancelled or held as treasury shares, which may then be cancelled, sold for cash or used to meet the company’s obligations under its employee share schemes. The authority shall expire at the conclusion of the next Annual General Meeting of the company or, if earlier, on June 30, 2023. As of April 8, 2022, the company had 46,185,874 ordinary shares in issue of which 675,411 ordinary shares are held in treasury. Anuncio • May 18
Science Group plc Intends to Appoint Susan Clement Davies to the Board as a Non-Executive Director Science Group plc announced that it intends to appoint Susan Clement Davies to the Board of Science Group plc as a Non-Executive Director. Ms. Clement Davies has over 25 years capital markets and investment banking experience, including 10 years at Citigroup/Salomon Smith Barney. She is currently Non-executive director of Evgen Pharma plc, Exploristics, MiNA Therapeutics and Scancell Holdings plc. Upcoming Dividend • May 12
Upcoming dividend of UK£0.05 per share Eligible shareholders must have bought the stock before 19 May 2022. Payment date: 17 June 2022. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of British dividend payers (4.8%). Lower than average of industry peers (2.0%). Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Peter Bertram was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 17
Investor sentiment improved over the past week After last week's 15% share price gain to UK£4.20, the stock trades at a trailing P/E ratio of 19.7x. Average forward P/E is 24x in the Professional Services industry in the United Kingdom. Total returns to shareholders of 112% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£6.02 per share. Anuncio • Feb 07
Science Group plc Appoints Jon Brett as Finance Director, Effective 1 March 2022 Science Group plc announced that Jon Brett was appointed to the Board of Science Group as Acting Finance Director on 10 August 2021. The Board confirmed Mr. Brett's appointment as Group Finance Director with effect from 1 March 2022. Price Target Changed • Jan 13
Price target increased to UK£5.61 Up from UK£5.11, the current price target is an average from 2 analysts. New target price is 25% above last closing price of UK£4.50. Stock is up 42% over the past year. The company posted earnings per share of UK£0.17 last year. Anuncio • Jan 13
Science Group plc Provides Revenue Guidance for the Full Year Ended December 31, 2021 Science Group plc provided revenue guidance for the full year ended December 31, 2021, the Group will report revenue in excess of £80 million. Anuncio • Dec 22
Science Group plc (AIM:SAG) commences an Equity Buyback Plan for 4,123,839 shares, representing 9.8% of its issued share capital, under the authorization approved on May 19, 2021. Science Group plc (AIM:SAG) commences share repurchases on December 17, 2021, under the program mandated by the shareholders in the Annual General Meeting held on May 19, 2021. As per the mandate, the company is authorized to repurchase up to 4,123,839 shares, representing 9.8% of its issued share capital. The minimum price (exclusive of expenses) which may be paid for each ordinary share is £0.01 and the maximum price which may be paid for each ordinary share is the higher an amount equal to 105% of the average of the middle market quotations for an ordinary share as derived from the AIM Appendix of the Daily Official List of London Stock Exchange for the five business days immediately preceding the day on which the ordinary share is contracted to be purchased and an amount equal to the higher of the price of the last independent trade of an ordinary share and the current highest independent bid for an ordinary share as derived from the London Stock Exchange Trading System. The shares purchased may either be cancelled or held as treasury shares, which may then be cancelled, sold for cash or used to meet the company’s obligations under its employee share schemes. The authority shall expire at the conclusion of the next Annual General Meeting of the company or, if earlier, on June 30, 2022. As of April 7, 2021, the company had 42,062,035 ordinary shares in issue of which 823,643 ordinary shares are held in treasury. Recent Insider Transactions • Sep 09
Executive Chairman recently sold UK£9.0m worth of stock On the 7th of September, Martyn Ratcliffe sold around 2m shares on-market at roughly UK£4.50 per share. This was the largest sale by an insider in the last 3 months. Martyn has been a seller over the last 12 months, reducing personal holdings by UK£14m. Anuncio • Sep 08
Science Group plc has completed a Follow-on Equity Offering in the amount of £18.557276 million. Science Group plc has completed a Follow-on Equity Offering in the amount of £18.557276 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,123,839
Price\Range: £4.5
Transaction Features: Regulation S; Subsequent Direct Listing Reported Earnings • Jul 28
First half 2021 earnings released: EPS UK£0.11 (vs UK£0.048 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£40.7m (up 10% from 1H 2020). Net income: UK£4.68m (up 133% from 1H 2020). Profit margin: 12% (up from 5.5% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year. Price Target Changed • Jul 26
Price target increased to UK£5.11 Up from UK£4.16, the current price target is an average from 2 analysts. New target price is 16% above last closing price of UK£4.40. Stock is up 86% over the past year. Anuncio • Jul 14
Science Group plc Provides Revenue Guidance for the Six Months to 30 June 2021 Science Group plc provided revenue guidance for the six months to 30 June 2021, the Group will report revenue in excess of £40 million. Anuncio • May 20
Science Group plc Approves Final Dividend Science Group plc approved final dividend of 4.0 pence per ordinary square at the AGM. Upcoming Dividend • May 13
Upcoming dividend of UK£0.04 per share Eligible shareholders must have bought the stock before 20 May 2021. Payment date: 18 June 2021. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (2.0%). Reported Earnings • Mar 10
Full year 2020 earnings released: EPS UK£0.17 (vs UK£0.041 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£73.7m (up 29% from FY 2019). Net income: UK£7.04m (up UK£8.71m from FY 2019). Profit margin: 9.6% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 10
Revenue beats expectations Revenue exceeded analyst estimates by 0.9%. Over the next year, revenue is forecast to stay flat compared to a 7.9% growth forecast for the Professional Services industry in the United Kingdom. Anuncio • Jan 12
Science Group plc Announces Executive Changes Science Group plc announced that after almost 7 years with the Group, Rebecca Archer, Group Finance Director, has advised the Board of her intention to resign to take up a new role. Rebecca has made a significant contribution to Science Group. The Board further announced that Sameet (Sam) Vohra has accepted the position of Chief Financial Officer Designate. Sam qualified as a Chartered Accountant with KPMG and has gained considerable experience in senior finance leadership roles in UK listed international businesses, including Group Financial Controller at TT Electronics PLC and Group Director of Finance at Spectris PLC, the FTSE 250 precision engineering company. Most recently, he was Interim Group Finance Director at Ted Baker PLC during their financial restructuring. Rebecca will leave the Group after completion of the 2020 audit and the posting of the Annual Report to shareholders. It is anticipated that Sam will be appointed to the Board in January with the formal transfer being completed in April. Over the next few months, a handover of responsibilities will be effected. Is New 90 Day High Low • Jan 06
New 90-day high: UK£2.90 The company is up 23% from its price of UK£2.35 on 08 October 2020. The British market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Professional Services industry, which is up 3.0% over the same period. Is New 90 Day High Low • Nov 27
New 90-day high: UK£2.68 The company is up 10.0% from its price of UK£2.43 on 28 August 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Professional Services industry, which is down 1.0% over the same period. Recent Insider Transactions • Oct 02
Executive Chairman recently sold UK£4.8m worth of stock On the 30th of September, Martyn Ratcliffe sold around 2m shares on-market at roughly UK£2.40 per share. This was the largest sale by an insider in the last 3 months. This was Martyn's only on-market trade for the last 12 months.